Neuromuscular Rehabilitation

Chapter

Abstract

Admit to: Inpatient or Outpatient Rehabilitation, depending on the reason for hospitalization

Keywords

Fatigue Morphine Flare Dehydration Sponge 

References

  1. 1.
    Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1998;160 Suppl 1:S6–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve. 2010;41(2):161–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle Nerve. 2007;35(3):291–302.PubMedCrossRefGoogle Scholar
  4. 4.
    Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009;73(20):1686–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999;164(1):82–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Wiebel M. [Non-invasive ventilation: possibilities and limitations in patients with reduced ability to cough]. Pneumologie. 2008;62 Suppl 1:S2–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Milner-Brown HS, Miller RG. Muscle Strengthening Through High-Resistive Weight Training in Patients with Neu- romuscular Disorders. Archives of Physical Medicine & Re- habilitation. 1988;69:14–19.PubMedGoogle Scholar
  8. 8.
    Kilmer DD. Response to resistive strengthening exercise training in humans with neuromuscular disease. American Journal of Physical Medicine & Rehabilitation. 2002;81:S121–S126.PubMedCrossRefGoogle Scholar
  9. 9.
    Dal Bello-Haas V, Kloos AD, Mitsumoto H. Physical therapy for a patient through six stages of amyotrophic lateral sclerosis. see comment. Phys Ther. 1998;78:1312–1324.PubMedCrossRefGoogle Scholar
  10. 10.
    Lunn MP, Willison HJ. Diagnosis and treatment in inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2009;80(3):249–58.Google Scholar
  11. 11.
    Ropper AH. The Guillain-Barre syndrome. N Engl J Med. 1992;326(17):1130–6.Google Scholar
  12. 12.
    Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57–65.Google Scholar
  13. 13.
    Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Bahou YG, Biary N, al Deeb S. Guillain-Barre syndrome: a series observed at Riyadh Armed Forces Hospital January 1984–January 1994. J Neurol. 1996;243(2):147–52.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797–810.PubMedCrossRefGoogle Scholar
  17. 17.
    Yaguchi H, Takei A, Honma S, Yamashita I, Doi S, Hamada T. Dropped head sign as the only symptom of myasthenia gravis. Intern Med. 2007;46(11):743–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986;36(5):729–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Uemura M, Nishimura K, Nakagawa M, et al. [A case of Lambert-Eaton myasthnic syndrome associated with small cell lung carcinoma representing as urinary retention]. Hinyokika kiyo Acta urologica Japonica. 2003;49(9):535–8.PubMedGoogle Scholar
  20. 20.
    Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol. 2004;24(1):31–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58(1):85–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Bird TD. Myotonic Dystrophy Type 1. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–1999 Sep 17 [updated 2011 Feb 08].Google Scholar
  24. 24.
    Worton R. Muscular dystrophies: diseases of the dystrophin-glycoprotein complex. Science. 1995;270(5237):755–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Butz M, Koch MC, Muller-Felber W, Lemmers RJ, van der Maarel SM, Schreiber H. Facioscapulohumeral muscular dystrophy. Phenotype-genotype correlation in patients with borderline D4Z4 repeat numbers. J Neurol. 2003;250(8):932–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies. Neuromuscul Disord. 1995;5(1):71–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Sutherland DH, Olshen R, Cooper L, et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev Med Child Neurol. 1981;23(1):3–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Neurol India. 2008;56(3):236–47.PubMedCrossRefGoogle Scholar
  29. 29.
    Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. [A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy]. Rinsho Shinkeigaku. 2011;51(10):743–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Sanyal SK, Johnson WW, Thapar MK, Pitner SE. An ultrastructural basis for electrocardiographic alterations associated with Duchenne’s progressive muscular dystrophy. Circulation. 1978;57(6):1122–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Valiyil R, Christopher-Stine L. Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep. 2010;12(3):213–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Mastaglia FL, Ojeda VJ, Sarnat HB, Kakulas BA. Myopathies associated with hypothyroidism: a review based upon 13 cases. Aust N Z J Med. 1988;18(6):799–806.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramsay ID. Electromyography in thyrotoxicosis. Q J Med. 1965;34(135):255–67.PubMedGoogle Scholar
  34. 34.
    Meyerson MD, Lewis E, Ill K. Facioscapulohumeral muscular dystrophy and accompanying hearing loss. Arch Otolaryngol. 1984;110(4):261–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology. 2006;66(2 Suppl 1):S20–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112(Pt 3):727–47.PubMedCrossRefGoogle Scholar
  37. 37.
    Tani K, Tomioka R, Sato K, et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest. 2007;54(3–4):295–302.PubMedCrossRefGoogle Scholar
  38. 38.
    Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.PubMedCrossRefGoogle Scholar
  39. 39.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Paty D, Studney D, Redekop K, Lublin F. MS COSTAR: a computerized patient record adapted for clinical research purposes. Ann Neurol. 1994;36(Suppl):S134–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Asgari N, Owens T, Frokiaer J, Stenager E, Lillevang ST, Kyvik KO. Neuromyelitis optica (NMO)—an autoimmune disease of the central nervous system (CNS). Acta Neurol Scand. 2011;123(6):369–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Lensch E, Jost WH. Autonomic disorders in multiple sclerosis. Autoimmune Dis. 2011;2011:803841.PubMedGoogle Scholar
  43. 43.
    Johansson KM, Nygren-Bonnier M, Schalling E. Effects of glossopharyngeal breathing on speech and respiration in multiple sclerosis: a case report. Mult Scler. 2011. doi: 10.1177/1352458511430223.
  44. 44.
    White LJ, McCoy SC, Castellano V, et al. Resistance training improves strength and functional capacity in persons with multiple sclerosis. Mult Scler. 2004;10(6):668–74.PubMedCrossRefGoogle Scholar
  45. 45.
    Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler. 2008;14(1):35–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Merson RM, Rolnick MI. Speech-language pathology and dysphagia in multiple sclerosis. Phys Med Rehabil Clin N Am. 1998;9(3):631–41.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Department of NeurologyBeth Israel Medical CenterNew YorkUSA
  2. 2.Department of Physical Medicine & RehabilitationBeth Israel Medical CenterNew YorkUSA

Personalised recommendations